Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by Sensorion

< Previous 1 2 3 4 Next >
Sensorion Reports 2022 First Half Results
From Sensorion
Via Business Wire
Sensorion Announces First Patient Enrolled in Proof-of-Concept Clinical Trial of SENS-401 for Residual Hearing Preservation During Cochlear Implantation
From Sensorion
Via Business Wire
Sensorion Receives Positive Opinion for Orphan Drug Designation for OTOF-GT for the Treatment of Otoferlin Gene-Mediated Hearing Loss From the European Medicine Agency
From Sensorion
Via Business Wire
Sensorion to participate in the Inner Ear Biology Workshop in September 2022
From Sensorion
Via Business Wire
Sensorion to Present at the Gene Therapy Neurological Disorders Europe, CASSS Bioassays Symposium and Cell & Gene Therapy Summit Conferences in July 2022
From Sensorion
Via Business Wire
Sensorion Announces Approval in Australia to Initiate Proof of Concept Clinical Trial of SENS-401 for Residual Hearing Preservation During Cochlear Implantation
From Sensorion
Via Business Wire
Sensorion to Participate in the LifeSci Partners 2nd Annual Genetic Medicines Symposium on June 29, 2022
From Sensorion
Via Business Wire
Sensorion to Present at the Inner Ear Disorder Therapeutics Summit in June 2022
From Sensorion
Via Business Wire
Sensorion to Present at the Gene Therapy Development and Manufacturing Conference in June 2022
From Sensorion
Via Business Wire
Sensorion Announces Approval in France to Initiate Proof of Concept Clinical Trial of SENS-401 for Residual Hearing Preservation During Cochlear Implantation
From Sensorion
Via Business Wire
Sensorion Publishes Results of Combined General Meeting Resolutions
From Sensorion
Via Business Wire
Sensorion to Attend the American Society of Gene & Cell Therapy (ASGCT) and Gene Therapy Analytical Development Conferences in May 2022
From Sensorion
Via Business Wire
Sensorion Provides Preliminary Documents for the Combined Shareholders’ General Meeting of May 31, 2022
From Sensorion
Via Business Wire
Sensorion Announces the Publication of Its 2021 Annual Financial Report
From Sensorion
Via Business Wire
Sensorion Full-Year 2021 Financial Results and Business Highlights
From Sensorion
Via Business Wire
Sensorion Will Participate in Chardan’s 6th Annual Genetic Medicines and Cell Therapy Manufacturing Summit Held Virtually on April 26, 2022
From Sensorion
Via Business Wire
Sensorion Publishes Results of Extraordinary General Meeting Resolutions
From Sensorion
Via Business Wire
Sensorion to Attend the Kempen Life Sciences, Cell & Gene Meeting on the Mediterranean Conferences in April 2022
From Sensorion
Via Business Wire
Sensorion Will Present at The H.C. Wainwright Gene Therapy and Gene Editing Virtual Conference on March 30th, 2022
From Sensorion
Via Business Wire
Sensorion Provides Preliminary Documents for the Extraordinary General Meeting of April 14th, 2022
From Sensorion
Via Business Wire
Sensorion Will Present at the Bioprocessing Summit Europe Conference on March 22, 2022 in Barcelona
From Sensorion
Via Business Wire
Sensorion Update on SENS-401
From Sensorion
Via Business Wire
Sensorion to Present Three Posters on SENS-401 in Cisplatin Ototoxicity Models at the Association for Research in Otolaryngology (ARO) 45th Annual MidWinter Meeting
From Sensorion
Via Business Wire
Sensorion to Present New Data on OTOF Gene Therapy at the Association for Research in Otolaryngology ARO 45th Annual MidWinter Meeting
From Sensorion
Via Business Wire
Sensorion Updates on SENS-401 Phase 2 trial in Sudden Sensorineural Hearing Loss
From Sensorion
Via Business Wire
Sensorion appoints Aniz Girach as Independent Board Member
From Sensorion
Via Business Wire
Sensorion appoints pharmaceutical industry veteran Scott D. Myers as Chairman of the Board and Independent Director
From Sensorion
Via Business Wire
Sensorion to present in person at “Jefferies London Healthcare Conference”
From Sensorion
Via Business Wire
Sensorion Surpasses Enrollment Target for SENS-401 in SSNHL, Results Available in January 2022
From Sensorion
Via Business Wire
Sensorion to Present at “Jefferies Gene Therapy / Editing Summit”
From Sensorion
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.